Research: Gene Editing for Lifelong Lipid Control
Update: 2025-11-13
Description
Steven Nissen, MD, and Luke Laffin, MD, discuss a groundbreaking phase 1 trial of a CRISPR-Cas9 gene-editing therapy targeting ANGPTL3. They explore its potential as a one-time treatment to significantly lower LDL cholesterol and triglycerides, with promising safety and efficacy data that could reshape lipid management.
Learn more about C5 Research at Cleveland Clinic.
https://my.clevelandclinic.org/research/c5research
Looking to refer a patient? Please reach out to our Physician Referral team Mon. - Fri., 8 a.m. - 5 p.m. (ET) at 855.751.2469.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
1.0x
